Skip to main content
Erschienen in: International Journal of Clinical Oncology 5/2011

01.10.2011 | Case Report

A case study of metastatic Xp11.2 translocation renal cell carcinoma effectively treated with sunitinib

verfasst von: Kazuyuki Numakura, Norihiko Tsuchiya, Takeshi Yuasa, Mitsuru Saito, Takashi Obara, Hiroshi Tsuruta, Shintaro Narita, Yohei Horikawa, Shigeru Satoh, Tomonori Habuchi

Erschienen in: International Journal of Clinical Oncology | Ausgabe 5/2011

Einloggen, um Zugang zu erhalten

Abstract

We report a case of Xp11.2 translocation renal cell carcinoma (RCC) whose lung metastases were effectively treated with sunitinib. A 43-year-old woman presenting with upper abdominal pain was diagnosed with a left renal tumor. Laparoscopic left radical nephrectomy was performed. Histopathological examination of the surgical specimen revealed a clear-cell carcinoma of the left kidney. Two years later, multiple lung metastases were detected and the patient was treated daily with 50 mg sunitinib. A computed tomography scan performed after 2 cycles of sunitinib treatment revealed partial regression of these metastases. The partial regression has been maintained for >3 years. In retrospective evaluation of the primary RCC, tumor cells showed strong nuclear staining for transcription factor E3 (TFE3) protein and TFE3 split-fluorescence in-situ hybridization revealed translocation involving the TFE3 gene. These findings strongly support diagnosis of Xp11.2 translocation RCC.
Literatur
1.
Zurück zum Zitat Argani P, Antonescu CR, Illei PB et al (2001) Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma. Am J Pathol 159:179–192PubMedCrossRef Argani P, Antonescu CR, Illei PB et al (2001) Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma. Am J Pathol 159:179–192PubMedCrossRef
2.
Zurück zum Zitat Motzer RJ, Hutson TE, Tomczak P et al (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27:3584–3590PubMedCrossRef Motzer RJ, Hutson TE, Tomczak P et al (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27:3584–3590PubMedCrossRef
3.
Zurück zum Zitat Winarti NW, Argani P, De Marzo AM et al (2008) Pediatric renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion. Int J Surg Pathol 16:66–72PubMedCrossRef Winarti NW, Argani P, De Marzo AM et al (2008) Pediatric renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion. Int J Surg Pathol 16:66–72PubMedCrossRef
4.
Zurück zum Zitat Choueiri TK, Mosquera JM, Hirsch MS (2009) A case of adult metastatic Xp11 translocation renal cell carcinoma treated successfully with sunitinib. Clin Genitourin Cancer 7:93–94CrossRef Choueiri TK, Mosquera JM, Hirsch MS (2009) A case of adult metastatic Xp11 translocation renal cell carcinoma treated successfully with sunitinib. Clin Genitourin Cancer 7:93–94CrossRef
5.
Zurück zum Zitat Zhong M, De Angelo P, Osborne L et al (2010) Dual-color, break-apart FISH assay on paraffin-embedded tissues as an adjunct to diagnosis of Xp11 translocation renal cell carcinoma and alveolar soft part sarcoma. Am J Surg Pathol 34:757–766PubMedCrossRef Zhong M, De Angelo P, Osborne L et al (2010) Dual-color, break-apart FISH assay on paraffin-embedded tissues as an adjunct to diagnosis of Xp11 translocation renal cell carcinoma and alveolar soft part sarcoma. Am J Surg Pathol 34:757–766PubMedCrossRef
6.
Zurück zum Zitat Tsuda M, Davis IJ, Argani P et al (2007) TEF3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition. Cancer Res 67:919–929PubMedCrossRef Tsuda M, Davis IJ, Argani P et al (2007) TEF3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition. Cancer Res 67:919–929PubMedCrossRef
7.
Zurück zum Zitat Malouf GG, Camparo P, Oudard S et al (2010) Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network. Ann Oncol 21:1834–1838PubMedCrossRef Malouf GG, Camparo P, Oudard S et al (2010) Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network. Ann Oncol 21:1834–1838PubMedCrossRef
8.
Zurück zum Zitat Mendel DB, Laird AD, Xin X et al (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9:327–337PubMed Mendel DB, Laird AD, Xin X et al (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9:327–337PubMed
9.
Zurück zum Zitat O’Farrell AM, Abrams TJ, Yuen HA et al (2003) SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101:3597–3605PubMedCrossRef O’Farrell AM, Abrams TJ, Yuen HA et al (2003) SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101:3597–3605PubMedCrossRef
10.
Zurück zum Zitat Chow LQM, Eckhardt SG (2007) Sunitinib: from rational design to clinical efficacy. J Clin Oncol 25:884–896PubMedCrossRef Chow LQM, Eckhardt SG (2007) Sunitinib: from rational design to clinical efficacy. J Clin Oncol 25:884–896PubMedCrossRef
11.
Zurück zum Zitat Stacchiotti S, Tamborini E, Marrari A et al (2009) Response to sunitinib malate in advanced alveolar soft part sarcoma. Clin Cancer Res 15:1096–1104PubMedCrossRef Stacchiotti S, Tamborini E, Marrari A et al (2009) Response to sunitinib malate in advanced alveolar soft part sarcoma. Clin Cancer Res 15:1096–1104PubMedCrossRef
12.
Zurück zum Zitat Ivan M, Bond JA, Prat M et al (1997) Activated ras and ret oncogenes induce over-expression of c-met (hepatocyte growth factor receptor) in human thyroid epithelial cells. Oncogene 14:2417–2423PubMedCrossRef Ivan M, Bond JA, Prat M et al (1997) Activated ras and ret oncogenes induce over-expression of c-met (hepatocyte growth factor receptor) in human thyroid epithelial cells. Oncogene 14:2417–2423PubMedCrossRef
13.
Zurück zum Zitat Wang SY, Chen B, Zhan YQ et al (2004) SU5416 is a potent inhibitor of hepatocyte growth factor receptor (c-Met) and blocks HGF-induced invasiveness of human HepG2 hepatoma cells. J Hepatol 41:267–273PubMedCrossRef Wang SY, Chen B, Zhan YQ et al (2004) SU5416 is a potent inhibitor of hepatocyte growth factor receptor (c-Met) and blocks HGF-induced invasiveness of human HepG2 hepatoma cells. J Hepatol 41:267–273PubMedCrossRef
Metadaten
Titel
A case study of metastatic Xp11.2 translocation renal cell carcinoma effectively treated with sunitinib
verfasst von
Kazuyuki Numakura
Norihiko Tsuchiya
Takeshi Yuasa
Mitsuru Saito
Takashi Obara
Hiroshi Tsuruta
Shintaro Narita
Yohei Horikawa
Shigeru Satoh
Tomonori Habuchi
Publikationsdatum
01.10.2011
Verlag
Springer Japan
Erschienen in
International Journal of Clinical Oncology / Ausgabe 5/2011
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-010-0154-6

Weitere Artikel der Ausgabe 5/2011

International Journal of Clinical Oncology 5/2011 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.